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The importance of circadian biology has rarely been considered in pre-clinical studies, and even more when
translating to the bedside. Circadian biology is becoming a critical factor for improving drug efﬁcacy and di-
minishing drug toxicity. Indeed, there is emerging evidence showing that some drugs are more effective at
nighttime than daytime, whereas for others it is the opposite. This suggests that the biology of the target
cell will determine how an organ will respond to a drug at a speciﬁc time of the day, thus modulating phar-
macodynamics. Thus, it is now time that circadian factors become an integral part of translational research.
Introduction
Differential Day/Night Outcomes in Humans
While the past two decades have witnessed a transformation in
the understanding of the molecular underpinnings of biological
clocks in model organisms, the bridge between circadian mech-
anisms and clinical studies remains incomplete. Reaching
across the divide between molecular and clinical systems re-
quires integration of circadian biology elements in medical prac-
tice (Bass and Lazar, 2016). For instance, a number of studies
demonstrated that heart attacks occur more frequently during
themorning hours, a ﬁnding that may be explained by vulnerabil-
ities to day/night ﬂuctuations in cardiovascular events such as
circadian variation in blood pressure and heart rate (for review,
see Thosar et al., 2018; day/night ﬂuctuations in thromboembolic
risk, Haus, 2007; arrhythmogenicity, Portaluppi and Hermida,
2007; inﬂammation, Winter et al., 2018). Cardiovascular system
challenges, such as cardiac surgery, provoke myocardial injury
in a predictive way, and it turns out that injury severity is highly
inﬂuenced by the time of day. Speciﬁcally, there is signiﬁcantly
lower risk when the surgery is performed in the afternoon
compared to the morning (Montaigne et al., 2018). A similar ef-
fect was reported in rodents. Interestingly, the day/night ﬂuctua-
tion in rodent cardiac injury is not present in animals with a dis-
rupted cardiomyocyte clock (Durgan et al., 2010). Furthermore,
in the hospital environment, these processes are disrupted by
enforced continuous activity throughout the day and night,
including maintained lighting, wakening for medication, delivery
of parenteral nutrition at night (in the opposite phase from the
daily appetite and digestive cycle), and delivery of medication
out of synchrony with drug-metabolizing enzyme expression.
Each of these events represents conﬂict between internal and
external timing. Similarly, staying up late at night and/or reading
with blue light-emitting screens may desynchronize intrinsic
circadian cycles with the natural light-dark cycle (Chang et al.,
2015; Chinoy et al., 2018). The short list of circadian pathology
signs includes emergencies that present at speciﬁc times of
day, such as nocturnal asthma (Burioka et al., 2010) and glucose
peak at dawn (Campbell et al., 1985). Evidence also suggests
there is circadian control of cognition (Chellappa et al., 2018),
memory performance (Kwapis et al., 2018), andmood (McClung,
2013), and a decline in the coherence of rhythmic processesmay
be a hallmark of age-related neurodegenerative disease (Musiek
and Holtzman, 2016). Further, both clinical studies and cross-
sectional evidence correlate shift work in human subjects with
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the heightened risk of disease, including metabolic, cardiovas-
cular, inﬂammatory, and neoplastic disorders (Buxton et al.,
2012; R€uger and Scheer, 2009; Wang et al., 2011). While shift
work also results in confounding non-circadian effects like
increased stress, eating, and smoking, these factors are also
known consequences of fragmented sleep and sleep depriva-
tion. These examples emphasize the exciting opportunity now
available to apply an understanding of molecular timekeeping
to human health.
Depression was one of the ﬁrst diseases associated with
circadian clock malfunction, observed as profound sleep distur-
bances and early morning awakenings (Gresham et al., 1965;
Zung et al., 1964). This phenomenon is due to rhythm dysfunc-
tion: a disturbed sleep-wake cycle is the main symptom of major
depression, and sleep disturbances are, in turn, a major risk fac-
tor for developing depression and other mood disorders. For
instance, patients who suffer from seasonal affective disorder
(SAD), a mood disorder that correlates with the extremely short-
ened daily light period during the winter season, have altered
levels of the dark-phase hormone melatonin and exhibit an
altered circadian cycle. SAD symptoms may be alleviated by
chronobiological therapy, such as bright light and melatonin
(Lewy et al., 2006). In fact, more or less all of the successful
mood disorder treatments seem to affect circadian rhythms,
and it appears as if rhythm stabilization, or even resetting the in-
ternal time, is helpful, if not essential, for therapeutic beneﬁt. In
modern societies, 80%of the world’s population is now exposed
to light during the night (Falchi et al., 2016; Straif et al., 2007), and
20% of European and 29% of US employees engage in rotating
shift work, actions that make them prone to rhythm disorders
and disease. Thus, our circadian clocks appear crucial for health,
and while many researchers studied circadian rhythms initially
from a fundamental scientiﬁc perspective, we have been sur-
prised—overwhelmed even—by the strong involvement of clock
malfunction in a number of diseases. Consequently, circadian
rhythm research has becomemore than a model area for biolog-
ical research; it will also impact future clinical research, substan-
tially and perhaps dramatically.
Oxaliplatin: How Chronobiology Cracked the Timing
Riddle
Drug development includes deﬁning a recommended dose for a
potential new compound, based on themajority of subjects, irre-
spective of timing, sex, age, lifestyle, or comorbidities. In this re-
gard, pharmaceutical companies have long tried to improve the
translational path from animal work to humans by increasing the
success rate of phase I, II, and III trials. However, numerous
drugs continue to fail in these trials despite optimal pharmacoki-
netics/pharmacodynamics (PK/PD), target speciﬁcity, tissue
availability, and careful patient group selection (Cook et al.,
2014; Morgan et al., 2018). Indeed, unanticipated or over-
whelming adverse effects represent severe limitations, and
both result in drug attrition (Waring et al., 2015) and post-market-
ing withdrawal of otherwise effective medications (Zhang et al.,
2012). For example, the toxicities of new agents sometimes
outweigh the slight beneﬁts in efﬁcacy at a population level,
thus making these new treatments too costly for the healthcare
system. As a result, medication safety represents a crucial chal-
lenge that needs to be prioritized and addressed with new con-
cepts and methods. While there are many factors that could
contribute to the failures in translating drug treatments from ro-
dent studies to humans (e.g., length of ovulatory cycles, low
LDL cholesterol, or lifespan), circadian factors might also be
involved in such failures. Do pre-clinical studies in nocturnal
animals not test the drugs at the optimal time of day to simulate
human biology? Conversely, does testing in humans not take
timing into account, either insufﬁciently or not at all?
An illustration of how ignorance of timing effects could lead to
abandoning a useful drug is provided by oxaliplatin. It has
become one of the main drugs against colorectal cancer world-
wide, despite its development being halted for excessive toxic-
ities in a phase I clinical trial by a leading pharmaceutical
company (Rhone-Poulenc-Rorer, France; (Extra et al., 1990).
The drug was sold to a just-created pharmaceutical group (De-
biopharm, Switzerland), which aimed at establishing oxaliplatin
safety and efﬁcacy through chronopharmacology. Circadian
toxicity and efﬁcacy studies in mice (Granda et al., 2002) guided
the design of clinical chronotherapy trials in patients with meta-
static colorectal cancer (reviewed in (Le´vi, 2001). The safety of
the drug was established following its administration as a circa-
dian chronomodulated infusionwith peak delivery rate at 16:00 in
phase I (Caussanel et al., 1990) and II (Levi et al., 1993) clinical
trials. The ﬁrst demonstration of its clinical efﬁcacy in colorectal
cancer was provided in a large phase II clinical trial using chrono-
modulated delivery (Le´vi et al., 1992), a ﬁnding that was later
conﬁrmed in randomized phase III trials (Le´vi et al., 1997).
Consequently, the integration of chronopharmacology that
accompanied the entire drug development process helped mini-
mize adverse effects and maximize therapeutic efﬁcacy through
the identiﬁcation of optimally timed drug delivery. Although to
our knowledge this case is the only well-documented example
of a misleading clinical trial linked to the lack of consideration
of circadian aspects, the prior failure is an outstanding example
that underscores the urgency for pre-clinical and clinical re-
searchers to take circadian time into consideration along the
clinical phases of the development of new drugs, as well as for
clinical tests of novel treatments.
The Clock System
Evolutionary Conservation and Relevance to Physiology
Deciphering the molecular core clock mechanism in the fruit ﬂy
led to the 2017 Nobel Prize in Physiology or Medicine awarded
to Michael Young, Michael Rosbash, and Jeffrey Hall. This
mechanism is fundamentally conserved within the animal
kingdom (Allada et al., 2001; Rosbash, 2009; Takahashi, 2017;
Young and Kay, 2001), although in mammals many clock com-
ponents are present in multiple copies, a fact that increases
the complexity and redundancy of the system (Clayton et al.,
2001). The PERIOD protein (PER) appears to have the same
structure and function in the core circadian clock of all animals,
although its function in response to adaptions of the core clock
to environmental signals varies among species (Albrecht, 2007;
Partch et al., 2014; Sandrelli et al., 2008). In spite of small differ-
ences between fruit ﬂies and mice in the cytoplasmic and gated
nuclear entry of PER proteins (Curtin et al., 1995; Shafer et al.,
2002), the basic molecular mechanism that generates rhythms
is highly similar in all examined animals. Moreover, this timing
mechanism is active in specialized brain areas (e.g., the acces-
sory medulla [AME] in the fruit ﬂy and the suprachiasmatic
2
htt
p:/
/do
c.r
ero
.ch
nucleus [SCN] of the mammalian hypothalamus) that have close
anatomical and functional connections to the optic system (light
input) and hormonal system (systemic output; (Helfrich-Fo¨rster,
2004, 2009). The master clocks in insects and mammals have
a neuromodulatory function and employ a wide variety of neuro-
peptides as signaling molecules (Maywood et al., 2011; Yoshii
et al., 2009). Both insect andmammalianmaster clocks inﬂuence
behavioral rhythms and connect to peripheral clocks via a com-
bination of humoral factors and the peripheral autonomic ner-
vous system.
In mammals, the relationship between the SCN and periph-
eral organs is well established. In order to adjust its rhythm,
the SCN receives information from the retina where intrinsically
photoreceptive retinal ganglion cells (ipRGCs) relay photic sig-
nals to the SCN via retinohypothalamic ﬁbers (Hannibal and
Fahrenkrug, 2002; Hattar et al., 2002). The SCN communicates
with the other clocks through autonomic innervation and, to a
second degree, through the regulation of systemic cues such
as body temperature, hormonal signaling, and feeding
(Mohawk et al., 2012). The SCN directly inﬂuences behavioral
and peripheral rhythms through neuropeptides (Cheng et al.,
2002; Loh et al., 2011), but it also controls peripheral clocks
indirectly via the autonomic innervation. For instance, the
SCN inﬂuences glucose homeostasis in the liver or glucocorti-
coid secretion by the adrenal glands via the paraventricular nu-
cleus (Ishida et al., 2005; Kalsbeek et al., 2004). Furthermore,
clocks from the heart, kidney, pancreas, lung, and thyroid
glands are also controlled by autonomic nervous connections.
In contrast, feeding and body temperature rhythms, modulated
by rest and activity cycles, are additional zeitgebers that entrain
the liver, pancreas, heart, and kidneys (Buhr et al., 2010; Dibner
et al., 2010).
The identiﬁcation of clock genes, and the cellular processes
instructed by those genes, conﬁdently explains how individual
neurons can act as autonomous oscillators. While the ability of
individual neurons to oscillate with circadian periodicities is
now well established (Herzog et al., 1998; Welsh et al., 1995),
in the recent past it was almost unimaginable that this phenom-
enon would be the case, given the long time constants involved.
Moreover, according to a recent ﬁnding, even astrocyte clocks in
the SCN can drive circadian rhythmicity of SCN neurons (Bran-
caccio et al., 2019). Although individual neurons possess this
remarkable autonomous capability, the ﬁeld has come to recog-
nize that the timing of physiology and behavior is the outcome of
autonomous oscillators that work together within and among tis-
sues in synchronized multi-oscillator ensembles. Intriguingly,
communication among clock cells leads to new properties at
the network or tissue level. For example, synchronization among
central clock neurons leads to the ability to encode and store day
length, which provides information about the seasons, a major
task of clocks in many organisms (Hastings et al., 2018; Hel-
frich-Fo¨rster, 2009; VanderLeest et al., 2007). This ability is not
present at the single-neuron level. Further, the central clock in
mammals is under the inﬂuence of both the external milieu—
mostly light—and the internal milieu, and it integrates signals
from other brain areas as well as from peripheral organs. These
signals all change the properties of the central clocks in impor-
tant ways, and the signals provide not only adaptability, but
also robustness and precision.
The identiﬁcation of the central molecular clock mechanism
provided the foundational ‘‘building blocks’’ that now allow an
understanding of how molecular feedback loops within individ-
ual neurons interact with similar mechanisms in other neurons.
This information creates a neuronal network with both properties
of the fundamental molecular oscillators and properties that
emerge from interactions with other neurons (Hastings et al.,
2018; Helfrich-Fo¨rster, 2009; VanderLeest et al., 2007). Clearly,
understanding biological timing at multiple levels of molecular,
cellular, and neural organization will be extremely salient for
translation of circadian biology to humans.
Translational Challenges
For practical reasons and workday organization, researchers
typically perform experiments during the daytime, but this design
creates unique difﬁculties when using laboratory rodents. The
most critical difference is oft-cited and obvious: mice and rats
are nocturnal. In fact, the National Association for Biomedical
Research in the US reports that mice and rats represent 95%
of all laboratory animals used for research. While mice and rats
are nocturnal and have a high metabolic rate and increased
behavioral activity and wakefulness during the night, humans
are diurnal and have their active period during the day. The
main problem is related to the fact that the majority of re-
searchers who use rodents perform their experiments during
the daytime, which corresponds to nighttime in humans, when
drugs are not usually administered. These fundamental biolog-
ical differences between nocturnal rodents and humans may
pose a challenge when trying to translate pre-clinical research
results to humans. As a result, the meaningful translation of
pre-clinical data to humans may be partly missed.
Daytime Experiments in Rodents Are Different from
Human Daytime
Given the strong time dependency exhibited by most behavioral
and metabolic tests, such as learning (Chaudhury and Colwell,
2002) or glucose tolerance tests (la Fleur et al., 2001), such var-
iations are important to consider for the design of experimental
protocols. However, the differences are in at least two respects
subtler and more difﬁcult to evaluate. First, rodents are poly-
phasic sleepers: although sleep is mostly consolidated into the
daytime, a rodent will show frequent short bouts of sleep and
waking during the night as well as the day in a way that has no
human equivalent (Simasko andMukherjee, 2009). The circadian
system and the sleep homeostasis are tightly connected but are
two separately driven systems in which the circadian drive for
wakefulness is uniquely timed to the increasing homeostatic
sleep drive in order to consolidate a 24 h rhythm in sleep and
wakefulness (Dijk and Czeisler, 1994). Thus, effects of ‘‘sleep
pressure’’ are much harder to evaluate, in spite of the high con-
servation of bothmolecular and synaptic aspects of sleep.More-
over, perhaps due to the normal frequency of sleep, a 4-h period
of enforced wakefulness represents a major perturbation equiv-
alent to much longer periods of sleep deprivation in a human be-
ing. Second, rodent metabolism is tuned to frequent eating,
which makes prolonged fasting an unnatural experience. Thus,
typical conditions of food deprivation represent mild starvation,
and a single day of fasting can result in up to 20% loss in body
weight (Dohm et al., 1983). Similarly, small changes in tempera-
ture create large changes in food consumption behavior. For
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example, mice kept at 33C ate 50% less than those kept at
20C, and mice kept at 11C ate 37% more (Bronson, 1987).
Overall, performing experiments during the animal’s sleep phase
can have major consequences on their physiology and the ability
to translate the ﬁndings to humans.
Nocturnal versus Diurnal Circadian Systems
Recently, the ancestral activity patterns of Mammalia were re-
constructed. The data indicate that mammals went through a
nocturnal bottleneck due to a temporal partitioning between
early mammals (night activity) and dinosaurs (day activity) during
the Mesozoic Era (Maor et al., 2017). Diurnality (day activity)
appeared in mammals with the extinction of dinosaurs in the
Cenozoic Era. With this change, several adaptations appeared
in diurnal mammals to optimize their physiology to the inverted
rest-activity cycle. Theoretically, three different types of adapta-
tions were possible. First, the molecular clock could be changed
so that it runs with the opposite phase in diurnal compared to
nocturnal animals. Second, the input sensors could be changed
such that they affect the molecular clock mechanism in opposite
ways, and third, the interpretation of the clock signal could be
opposite, which would lead to appropriate regulation of physio-
logical pathways.
Deoxyglucose uptake experiments revealed that in the SCN,
the rhythm of metabolic activity is similar in both nocturnal and
diurnal animals (Schwartz et al., 1983). At the molecular level,
the expression of clock genes shows the same phase in diurnal
and nocturnal SCN, and their light-dependent synchronization is
comparable (Mrosovsky et al., 2001). Interestingly, the behav-
ioral response to light perceived at night is similar in nocturnal
and diurnal animals as well. They respond with a delay of clock
phase in response to light during the early part of the dark phase,
whereas clock phase is advanced if light is perceived during the
late portion of the dark phase (Mahoney et al., 2001). This ﬁnding
indicates that the SCN clock ticks in a similar manner regardless
of the activity preference of the species: there is a universal
connection to solar time. However, in SCN neurons, rhythmicity
of putative clock target factors displays opposite phases in
diurnal and nocturnal animals, as exempliﬁed by transforming
growth factor alpha (TGFa; Tournier et al., 2007). Interestingly,
brain clock gene expression outside the SCN (Vosko et al.,
2009) and in peripheral tissues (Mure et al., 2018) displays
roughly opposite phases. Additionally, hormones (glucocorti-
coids, leptin, and ghrelin) andmetabolites (glucose and free fatty
acids) show opposite cycling phases in diurnal and nocturnal ro-
dents (Kumar Jha et al., 2015), results that suggest the difference
between nocturnal and diurnal animals may lie downstream of
the SCN.
There is, however, evidence that diurnal and nocturnal mam-
mals differ in the input pathways to the clock. For example, the
diurnal species Tupaia (tree shrew) displays arrhythmic activity
patterns under constant darkness conditions (Meijer et al.,
1990), whereas nocturnal mice show rhythmic, free-running ac-
tivity with a period slightly less than 24 h under these same con-
ditions. Under constant bright light conditions, however, the
situation is inverted: nocturnal rodents can become arrhythmic,
whereas the diurnal Tupaia displays robust, rhythmic, and free-
running activity (Meijer et al., 1990). The acute light response is
also qualitatively different (Meijer et al., 1990). Taken together
with their similar core clock phases, the difference between
diurnal and nocturnal species may be at the cellular and
neuronal network level rather than the genetic level. Evidence
for anatomical adaptation to diurnality comes from the observa-
tion that in diurnal animals, classical photoreceptors play a
more important role in the light response than in nocturnal
animals (van Diepen et al., 2013). Older studies revealed that
the ratio between light-suppressed and light-activated cells dif-
fers between diurnal and nocturnal animals (Meijer et al., 1989),
results that suggest the light-input mechanism is not identical.
This observation is consistent with the ﬁnding described above
that constant light and darkness do not have the same effect
on activity patterns in animals that occupy opposing temporal
niches. Taken together, it appears that adaptation to diurnality
may also include pathways upstream of the SCN. It also needs
to be mentioned that the light sensitivity for phase entrainment
is much higher in nocturnal animals.
The observations described above are largely consistent with
a recent study that systematically analyzed the diurnal transcrip-
tome in neural and peripheral tissues of the baboon (Papio
anubis; Mure et al., 2018). Comparison between the diurnal ba-
boon and the nocturnal mouse revealed that, with the exception
of the SCN, the peak phase of most clock genes is opposite be-
tween comparable tissues. Since common cycling clock target
genes in peripheral tissues of baboon andmouse did not consis-
tently show an opposite expression pattern (Mure et al., 2018), it
is unlikely that there is a single nocturnal-diurnal ‘‘switch’’ down-
stream of the SCN. Indeed, in all mammalian species, indepen-
dent of nocturnal or diurnal activity, the pineal gland secretes
melatonin exclusively at night (Pe´vet, 2003). This phenomenon
suggests that in peripheral tissues, temporal organization is
diverse and may be autonomous. The dominance of feeding-
fasting cycles on the clock phase entrainment of peripheral or-
gans (but not the SCN) in mice and rats (Damiola et al., 2000;
Stokkan et al., 2001), and probably also in humans, suggests
that time of food uptake is a main synchronizer in peripheral or-
gans. Insulin signaling drives the synthesis of the clock protein
PER to entrain circadian rhythms with feeding time (Crosby
et al., 2019). This may explain the opposite cycling of peripheral
oscillators observed between nocturnal and diurnal species,
because feeding times are following activity patterns. Although
clock rhythms in the SCN are comparable in both nocturnal
and diurnal species, the peripheral oscillators are not. However,
all species maintain a constant phase relationship between the
SCN and peripheral organs in order to organize body physiology
in a temporal manner. As mentioned above, the rodent SCN in-
tegrates the light entrainment into the autonomous molecular
and electrical oscillations, which in turn are relayed to the body
via neural and humoral pathways. Whereas glucocorticoids
communicate SCN signals to peripheral clocks, feeding signals
can entrain peripheral clocks without SCN inﬂuence (Damiola
et al., 2000), which appears to use insulin and IGF-1 as major
signaling pathways (Crosby et al., 2019). Hence, model organ-
isms for developing treatments of clock-related diseases in hu-
mans may be useful, taking into consideration the opposite
phase relationship between the SCN and peripheral clocks in
nocturnal species compared to diurnal species.
Circadian Pharmacokinetics
Not only will the experimental manipulations performed during
rodent sleep time affect their translation to humans, but
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administration of drugs at different times of the day can also lead
to various outcomes due to variations in pharmacokinetics. Drug
pharmacokinetics are governed by its physicochemical charac-
teristics and absorption, distribution, metabolism, and excretion
(ADME) properties. The potential circadian modulation of phar-
macokinetics, chronopharmacokinetics, was reviewed as early
as the 1980s (see Reinberg and Smolensky, 1982), and it exam-
ined the chronobiological regulation of factors involved in
different aspects of ADME. Such interactions range from the
macroscopic impact of activity and feeding cycles on factors
such as gastric emptying and blood-ﬂow rate on drug absorption
and distribution, to circadian regulation of expression levels of
enzymes and transporters involved in metabolism and excretion
of xenobiotics such as drugs (Erkekoglu and Baydar, 2012).
The ADME properties of all drugs can be subject to large circa-
dian variations, as shown for hundreds of compounds in labora-
tory rodents and humans (Levi and Schibler, 2007). To some
degree, they are affected by circadian rest-activity patterns
such as meal timing, the general sleep-wake cycle, and physical
activity, all of which modulate blood pressure and ﬂow. The de-
gree of impact depends not only on the routes of administration
and excretion, but also on circadian modulation of gastric pH
and gastrointestinal motility, both of which inﬂuence drug ab-
sorption. Blood ﬂow and capillary perfusion, by contrast, impact
drug absorption from the gastrointestinal tract, distribution to tis-
sues and target organs, and even excretion through glomerular
ﬁltration rate in the kidneys (Ballesta et al., 2017; Dallmann
et al., 2014, 2016). Recent research demonstrated that xenobi-
otic efﬂux by the blood-brain barrier is also under circadian regu-
lation, which could inﬂuence the response to drug treatments
that target the brain (Zhang et al., 2018).
There are other drug-speciﬁc effects that depend on circadian
regulation of xenobiotic detoxiﬁcation pathways (Zmrzljak and
Rozman, 2012). The expression of phase I and II drug-metabo-
lizing enzyme families, such as CYP450, SULT, UGT, NQI,
EPH, GSTH, and NAT, is regulated by CLOCK/BMAL1, REV-
ERB/ROR, or circadian clock-regulated PARbZip transcription
factors (Gachon et al., 2006; Kang et al., 2007; Tanimura et al.,
2011). CYP450 activity also depends on heme availability, which
is under circadian control because the rate-limiting enzyme in
heme biosynthesis (ALAS1) is driven by the CLOCK paralog
NPAS2 (Froy, 2009). Finally, phase III detoxiﬁcation through hep-
atobiliary or renal excretion and reabsorption of parent drug or
metabolites is not only affected by perfusion and activity levels,
as described above, but these processes can also bemodulated
through circadian regulation of transporter protein expression
levels, including the ABC/MDR, OAT, OCT, and MRP families
(Gachon and Firsov, 2011). Since these same proteins are
involved in the transport into and out of target tissues and cells
in the organism (Scherrmann, 2009), such circadian regulation
can equally affect the absorption and distribution aspects of
the drug pharmacokinetic proﬁle.
In summary, the impact of circadian modulation on the ADME
properties of (and thus relevance of chronopharmacokinetics for)
the therapeutic effect of a given drug will depend strongly on the
degree to which the compound interacts with transporters dur-
ing the processes of absorption, distribution, and excretion,
and the amount and role of metabolism it undergoes. Conse-
quently, the pharmacokinetics of a given drug may differ de-
pending on the time of the day it is delivered, an aspect that
has not yet been systematically examined in clinical research,
drug development, registration by regulatory agencies, or med-
ical and pharmacy practices. Speciﬁc attention should be paid to
drugs with a narrow therapeutic window, or when a strong corre-
lation is found between the pharmacodynamic effect and the
plasma or tissue levels of a drug that acts on a therapeutic target
that is itself under circadian regulation (Bruguerolle and Lemmer,
1993). All of these parameters can profoundly differ in model
organisms.
Treatment Outcome Depends on the Time
of Administration
Drug efﬁcacy may depend not only on drug pharmacokinetics,
but also on the internal status of the clock and clock-regulated
genes, which will in turn determine the sensitivity of target cells
and pathways to the available drug at speciﬁc times of the
day. Chronopharmacological approaches to treating diseases
revealed that efﬁcacy is improved, and side effects reduced,
when the administration is appropriately timed. For instance,
levels of antibodies in response to inﬂuenza vaccination are
higher in the morning compared to the afternoon (Long et al.,
2016), a phenomenon that could be due to baseline differences
in antibody titers, which vary during the day (Kurupati et al.,
2017). Patients who received a sustained release formulation
of indomethacin for hip or knee osteoarthritis presented a 33%
incidence of adverse events after morning dosing, compared
to 7% after evening dosing. Antalgic and anti-inﬂammatory
efﬁcacies were most effective following evening dosing in sub-
jects with predominantly nocturnal or morning pain (Levi et al.,
1985). In asthmatic children, a sustained-release preparation
of theophylline (Theo24R) was recommended to be taken in
the evening, based on improved efﬁcacy of standard theophyl-
line preparations dosed at this time of day (Smolensky et al.,
1987). However, in a randomized, double-blind, and placebo-
controlled study, the serum levels of Theo24R exceeded the
toxic threshold of 20 mg/L in the majority of children that took
the medication daily for 6 days at 21:00, as compared to none
when taken at 06:00 (Smolensky et al., 1987). While Theo24R
effectively improved airway functions, there were no statistically
signiﬁcant differences in drug efﬁcacy according to dosing time
in this study, in contrast to large differences in steady-state phar-
macokinetics (Smolensky et al., 1987). Theo24R later proved to
be too toxic (toxicity symptoms ranging from abdominal pain
to cardiac arrhythmias to seizures) at the recommended evening
intake and was withdrawn from the market (Cooling, 1993;
Journey and Bentley, 2018). In oncology, the chronomodulated
administration of combination chemotherapy with oxaliplatin,
5-ﬂuorouracil, and leucovorin for the treatment of metastatic
colorectal cancer produced severe mucosal toxicities in only
14% of patients as compared to 76% of those who received
‘‘standard’’ infusions at a constant rate for 5 days. This protocol
signiﬁcantly increased the rate of patients with an objective treat-
ment response from 29% to 51% (Le´vi et al., 1997). Ameta-anal-
ysis of three international randomized trials that involved 842
patients with metastatic colorectal cancer further demonstrated
that the three-drug chronotherapy schedule signiﬁcantly im-
proved overall survival in men, but not women, independent of
all known prognostic factors (Giacchetti et al., 2012). These re-
sults triggered further pre-clinical and clinical studies aimed at
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providing a reliable and real-time metric of the circadian timing
system for personalizing chronotherapeutic strategy and deliv-
ery. Such circadian biomarker assessments are clearly neces-
sary for customizing chronotherapeutics according to the
internal phase of the patient. Moreover, in a pooled analysis of
1,077 cancer patients, cases of circadian disruption were asso-
ciated with signiﬁcantly worse survival and quality of life, as
compared to robustness, a ﬁnding that supports the need to
develop clock-targeted therapies for these patients (Ballesta
et al., 2017).
Several large studies highlight the relevance of circadian
timing of treatments for clinical tolerability and/or efﬁcacy in
allergic, rheumatologic, sleep, cardiovascular, and malignant
diseases (Table 1). It is interesting to note that a majority of drugs
(e.g., angiotensin converting-enzyme [ACE] and angiotensin re-
ceptor blockers, calcium channel blockers, and diuretics) show
greater efﬁcacy upon evening administration. In contrast, gluco-
corticoids show the opposite effect, with greater efﬁcacy in the
morning. For instance, standard prednisone treatment for rheu-
matoid arthritis was compared with evening intake of a chrono-
prednisone tablet, which automatically released the drug during
the early morning (04:00 when taken at 20:00); the chrono-
release tablet ameliorated median joint stiffness by 22%, as
compared to 0.4% for standard prednisone therapy (Buttgereit
et al., 2008). This efﬁcacy was replicated in another large, ran-
domized, double-blind, and placebo-controlled study that
showed the efﬁcacy of modiﬁed-release prednisone treatment
for rheumatoid arthritis (Buttgereit et al., 2013). Thus, systems
chronopharmacology and circadian biomarker studies are now
shaping chronotherapeutics for chronic diseases in the era of
Table 1. Efﬁcacy of a Morning versus Evening Schedule of Drug Administration
Drug Type Subjects Type of Study
Most Efﬁcacious
Delivery Time Reference
Ramipril ACE inhibitors and
angiotensin receptor
blocker
115 randomized evening Hermida and Ayala, 2009
Olmesartan ACE inhibitors and
angiotensin receptor
blocker
123 randomized evening Hermida et al., 2009
Telmisartan ACE inhibitors and
angiotensin receptor
blocker
215 randomized evening Hermida et al., 2007
Nifedipine calcium channel
blocker
180 randomized evening Hermida et al., 2008b
Torasemide diuretics 113 randomized evening Hermida et al., 2008a
Doxazosin diuretics 111 randomized evening Pickering et al., 1994
Amiodipine/valsartan combinations 203 single/combined evening Hermida et al., 2010
Hydrochlorothyazide/
valsartan
combinations 204 open-label, blinded
end-point
evening Hermida et al., 2011
Simvastatin statins 172 double-blind, placebo-
controlled
evening Saito et al., 1991
Simvastatin statins 132 randomized, double-
blind, placebo-controlled
no difference Kim et al., 2013
Fluvastatin ER statins 197 double-blind, multicenter no difference Scharnagl et al., 2006
Ezetimibe-simvastatin statins 171 randomized, cross-over morning Yoon et al., 2011
Ketprofen analgesics 117 randomized,
double-blind
no difference Perpoint et al., 1994
Aspirin COX inhibitor 290 randomized crossover no difference Bonten et al., 2015
Aspirin COX inhibitor 350 randomized, double-
blind, placebo-controlled
evening Ayala et al., 2013
Prednisone
(for arthritic pain)
corticosteroids 288 randomized,
double-blind
morning Buttgereit et al., 2008
Mometasone
(for asthma)
corticosteroids 268 placebo-controlled no difference Karpel et al., 2005
Tiotropium beta(2)-adrenergic
agonists
121 randomized, double-
blind, placebo-controlled
no difference Calverley et al., 2003
Montelukast leukotriene receptor
antagonist
343 randomized, placebo-
controlled
evening Altman et al., 1998
The table is modiﬁed fromDeGeorgi et al., (2013), with permission from Elsevier, and includes studies reported in PubMed until September 2018 using
the term ‘‘chronotherapy.’’ Studies with n > 100 are reported with the drug used and its classiﬁcation. The number of subjects and the study design are
shown, and the time at which the best efﬁcacy in treatment outcome was observed is reported.
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precision and personalized medicine (Ballesta et al., 2017). It is
interesting to note that the majority of top-selling drugs target
genes whose expression is circadian and who have half-lives
shorter than 6 h. Thus, the timing of administration is critical for
drugs with such short half-lives (Zhang et al., 2014). An example
of a short-lived compound is aspirin, which targets circadian
clock-regulated genes (e.g., PTGS1 or cyclooxygenase-1, alias
COX1), and modulates blood pressure when delivered in low
doses at nighttime (Hermida et al., 2005).
Potential Solutions to Improve Clinical Outcomes in
Drug Trials
Considerations of Time in Pre-clinical Research
As noted above, a key difﬁculty in translating bench ﬁndings to
the clinic results from pre-clinical research performed on ro-
dents. The mismatch between rodent and human phase could
easily be corrected by inverting the light-dark cycle of the rodent,
thereby eliminating the necessity for the scientist to perform ex-
periments during the night. Is the solution to incorporate diurnal
rodents in pre-clinical drug testing? Not necessarily—this design
would not avoid the need for testing drugs at different times of
the day to reveal their respective times of optimal efﬁcacy and
diminished toxicity, since these results may depend not only
on the rhythmicity of drug metabolism and target but also on
the readouts. We strongly advocate that the disease model—
not its diurnality—should be the strongest argument for testing
drugs. Additionally, the number of existing diurnal rodents is
small (e.g., the Mongolian gerbil [Meriones unguiculatus], the
degu [Octodon degus], the African [Nile] grass rat [Arvicanthis ni-
loticus], and the antelope ground squirrel [Ammospermophilus
leucurus]), and their value as experimental models for drug
development deserves to be explored (Reﬁnetti and Kenagy,
2018). An easier and more natural approach would be to reverse
or alter light-dark cycles in the normal rodent (mouse and rat)
housing environment, in order to perform the experimental
work during the day without phase-related artifacts. For
instance, turning off lights from 10:00 to 20:00 would allow ani-
mal caretakers to perform their husbandry tasks in light in the
morning, while the animal experimentation could take place in
darkness (Hawkins and Golledge, 2018). A number of tests
demonstrated greater behavioral and cognitive performance at
nighttime (Roedel et al., 2006). For instance, tonic pain sensitivity
in rodents is greatest during daytime (Perissin et al., 2000), a
ﬁnding that could have implications for drug efﬁcacy being mis-
interpreted or completely missed solely due to the rhythmicity of
the readout. One could also use commercially available isolated
housing cabinets with independent light-dark cycles, or gener-
alize autonomic animal chronobiologic facilities where light-
dark schedules are programmable in time (Tampellini et al.,
1998). There are obvious animal-facility management implica-
tions to such approaches, in order to avoid accidental light
contamination (e.g., from corridors) or noise that could entrain
the animal’s rhythm. Lamps with light spectra to which rodents
have reduced sensitivity (e.g., red or red-orange light and
narrow-wave-length sodium vapor lamps) can entrain rodents
(Peirson et al., 2018). Night-vision goggles or cameras could pro-
vide the means of performing experiments in darkness. Another
solution would be to use automated systems to collect data at
nighttime in the absence of human interventions.
Improving Therapeutics by Targeting the Clock System
While controlling the animal’s diurnal cycle and considering the
time of the day in pre-clinical drug treatments, another way of
improving therapeutic outcome is to target the clock system. A
recent analysis by Zhang, Lahens, and colleagues showed that
disease genes are highly enriched for circadian regulation
(Zhang et al., 2014). Many, but not all, of these clock-regulated
genes are mutated in diseases such as Alzheimer’s disease,
schizophrenia, and Down syndrome and are involved in neuro-
degeneration. Other circadian-related diseases include obesity,
type 2 diabetes, and cancer. Aging causes circadian transcrip-
tome reprogramming, which is differentially regulated in organs
(Sato et al., 2017). Given that circadian clocks regulate most
human physiology (Skarke et al., 2017), where half of all human
protein-coding genes are clock regulated (including drug trans-
porters, metabolizing enzymes, and targets; Ruben et al.,
2018), the clock system has received renewed interest as a phar-
macological target. Multiple pilot small-molecule screens identi-
ﬁed circadian clock-modifying compounds (e.g., He et al., 2016;
Hirota et al., 2012; Solt et al., 2012) that are under investigation
for wide-ranging indications including cancer, neurodegenera-
tion, endocrinology, and asthma. Moreover, an ever-increasing
number of studies postulate distinct and elegant mechanisms
by which the molecular clockwork can modulate drug metabo-
lizing enzymes, transporters, and targets (Anaﬁ et al., 2014;
Pizarro et al., 2013; Zhang et al., 2014). For short-acting
molecules, these mechanisms could be exploited to improve
the therapeutic index and balance between toxicity and efﬁcacy.
However, the pathways to translational application of this
knowledge remain unclear. We envision multiple possibilities
beyond conventional chronopharmacology per se.
Targeted Clock Suppression or Enhancement. Given that the
basic circadian mechanism is a feedback loop of transcrip-
tional/translational activation and repression, any suppression
of circadian clock function essentially blocks the mechanism to-
ward one extreme or the other. For example, in wound healing,
Bmal1 deletion (the ‘‘positive limb’’ in themolecular clock) results
in hyperkeratosis and insufﬁcient cell proliferation, while Per2
deletion (the ‘‘negative limb’’) results in hyperproliferation of
ﬁbroblasts and keratinocytes but insufﬁcient keratin and
collagen secretion (Kowalska et al., 2013). Thus, it is possible
that transient clock suppression by targeting one or the other
limb could be useful to push a normal circadian process toward
a therapeutically useful extreme. On the other hand, enhancing
the circadian rhythm may offer an elegant ‘‘do no harm’’ mecha-
nism for therapies including cancer (Iurisci et al., 2006; Kiessling
et al., 2017). For example, in one study, disrupted circadian clock
function led to a progression from non-alcoholic fatty liver
disease (NAFLD) to ﬁbrosis and cancer (Kettner et al., 2016).
This change occurred on its own and was even enhanced by
genetic disruption of clock genes. Recent literature points to
clock system disruption as causal in neurodegeneration
(Hastings and Goedert, 2013; Musiek et al., 2018). It stands to
reason that improving clock function, e.g., through enhancing
BMAL1/CLOCK or inhibiting REV-ERBa activity, could improve
outcomes. In support of this hypothesis, a recent study from
Montaigne et al. reported that the incidence of major adverse
cardiac events was lower in patients who undergo cardiac sur-
gery in the afternoon compared to the morning. Consistent
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with a greater expression of REV-ERBa in the human myocar-
dium in the morning, deletion of REV-ERBa function or its
blockade using a selective antagonist (SR8278) at the sleep-
to-wake transition protects mice from myocardial injury (Mon-
taigne et al., 2018).
Leveraging Circadian Regulation. As pre-clinical researchers
discover new mechanisms by which the circadian clock modu-
lates physiology, each of thesemechanisms provides a potential
intervention point for therapy. For example, circadian clock pro-
teins interact in many different ways to control drug metabolism
and transport. Anaﬁ et al. showed that a mechanistic under-
standing of drug transport enables design and hypothesis
testing to improve the therapeutic index (Anaﬁ et al., 2017).
GLUT2, a solute carrier and drug transporter, is clock-regulated
in mice and humans with high amplitude. Timing the administra-
tion of streptozocin, a chemotherapeutic agent and GLUT2 sub-
strate, early in the wake phase dramatically decreases its
toxicity, as evidenced by reduced weight loss in comparison to
administration early, in the inactive phase. Recently, researchers
reported a robust clock machinery in the peripheral auditory sys-
tem that is associated with greater vulnerability of mice to a noise
trauma delivered during the active compared to the inactive
phase (Meltser et al., 2014). The improved recovery from the
noise exposure during the inactive phase was associated with
the ability of the cochlea to increaseBdnf expression in response
to noise, a phenomenon that did not occur during the active
phase. Interestingly, BDNF is circadian in the brain, where it
peaks during the active phase (Marosi and Mattson, 2014), as
well as in the cochlea (Basinou et al., 2017). Treatment with an
agonist of the BDNF receptor TrkB, namely di-hydroxyﬂavone
(DHF), effectively protects hearing in mice from noise trauma
when delivered at night, but not during the day (Meltser et al.,
2014). If the compound had not been tested during nighttime,
the efﬁcacy of this molecule would have been missed, and the
fundamental relevance of circadian mechanisms and TrkB
signaling in the treatment of hearing disorders would have
been ignored. Winter et al. found that myeloid cell recruitment
to atherosclerotic lesions in mice oscillates with a peak at the
onset of daytime, a process regulated by the rhythmic release
of myeloid cell-derived CCL2 (Winter et al., 2018). However,
myeloid cell adhesion to microvascular beds peaks at the onset
of nighttime. Treatment at nighttime with RS102895, a CCR2
antagonist, reduces atherosclerotic lesion formation, whereas
daytime treatment is not effective (Winter et al., 2018). Hundreds
of other drug-metabolizing enzymes, transporters, and drug tar-
gets are also clock-regulated, many with high amplitude. This
knowledge could be leveraged to improve the action of existing
drugs, but also incorporated into trials of new drug candidates.
Figure 1. Toward the Use of Chronopharmacology for Precision and Personalized Medicine
The current state of the art indicates that although the impact of circadian rhythms on biological outcomes is acknowledged (e.g., academia and industry aremore
cautious in performing experiments at similar times of the day), minimal attention is given to the powerful impact that circadian mechanisms may have on drug
development. Animal and clinical work show a strong correlation between clock malfunction and disease. However, there are inherent translational challenges in
drug R&D such as the use of rodents (nocturnal animals) tested at daytime, which has a large impact on physiology and thus complicates the translation to
humans. Clinically, there is no emphasis put on the timing of drug administration; rather, the focus is on healthcare logistics and patient convenience. Important
caveats include the fact that drug ADME properties (absorption, distribution, metabolism, and excretion) are controlled by circadian mechanisms leading to
altered bioavailability at different times of the day, and that the circadian status of the pathway targeted by the drug will also impact outcome. Thus, integrating
circadian knowledge on ADME properties and the activity of the targeted pathway will lead to increased efﬁcacy and diminished side effects. Since themajority of
FDA-approved drugs have circadian targets, timing drug delivery could have a large impact on the effectiveness of target activation or inhibition. What solutions
are available to achieve such medical improvements? While the use of diurnal rodents would require decades to develop optimal disease models, using the
acquired knowledge in nocturnal animals would bemore powerful by including shifts in the light cycle or performing experiments during the animal’s active time—
depending on the readout and the physiology tested. Implementing circadian aspects in pre-clinical research will lead to new discoveries that, once applied in
clinical trials (e.g., using chronotype or circadian biomarkers), may improve the impact on human health by optimizing drug efﬁcacy and reducing side effects. The
case of Oxaliplatin is a pioneering example that led to chronomodulated infusion, with maximized treatment efﬁcacy and minimized adverse effects.
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Clock-Independent Modulation of Gene Expression. Finally,
another possibility is to develop therapeutic drugs that target
clock proteins, irrespective of their clock function. Indeed,
comprehensive chromatin immunoprecipitation sequencing
(ChIP-seq) studies suggest that individual clock proteins like
CRY1 and CRY2 might associate with non-circadian promoters
independently of other clock proteins (Koike et al., 2012), and
drugs affecting these clock proteins might therefore exert
entirely clock-independent effects upon transcription of these
genes. Thus, clock protein-targeting drugs could also exert dis-
ease-pertinent clock-independent transcriptional effects.
The Importance of Understanding Circadian Alignment
Conditional mutagenesis has elucidated the contribution of indi-
vidual tissue clocks to homeostasis at different times across the
sleep-wake cycle. When controlled for time of day, nutrient sta-
tus (e.g., fasting or feeding), and developmental age (using
inducible alleles), such studies reveal that local clocks of distinct
organs partition anabolic and catabolic processes to different
times of day (Peek et al., 2013; Perelis et al., 2015). An area
that remains in its infancy is our understanding of how special-
ized pacemaker clock neurons and astrocytes might be linked
within circuits involved in energy balance, sleep, mood, learning,
and memory. As clocks are robust and interconnected, a chal-
lenge has been that perturbation of individual factors in an animal
may lead to compensatory upregulation in a second limb. Ge-
netic strategies must control for such compensatory gene regu-
latory loops. For instance, in experimental design, investigators
may considermonitoring behavioral and physiological endpoints
under free-running conditions, or using cell-based models
including three-dimensional organoids from different tissues
(Yamajuku et al., 2012) that are devoid of the complex nutritional
factors that modulate rhythmicity in an intact animal. Work in eu-
bacteria and plants (Dodd et al., 2005; Ouyang et al., 1998)
demonstrated growth and reproductive advantage when
intrinsic clock time is aligned with the external light-dark cycle.
Advancing the concept of circadian alignment and its effect in
mammalian organisms remains a critical goal in mapping the
role of biological clocks in human health.
Conclusions
There is clear evidence for the involvement of circadian mech-
anisms in diseases, yet there is only sparse recognition of its
importance in pre-clinical and clinical research. This article
has highlighted the hurdles when performing experiments in
nocturnal rodents during their sleep time, and how this exper-
imental design is likely to affect translation to humans. We
advocate a paradigm shift in pre-clinical research using circa-
dian knowledge in order to develop therapeutic interventions
appropriately timed by considering the drug kinetics and the
circadian status of the target and the disease (Figure 1). Chro-
notherapy, which considers the time of day, may signiﬁcantly
improve clinical trial success and ultimately patient care.
Since sleep-wake cycles are driven by the coupling of the
circadian clock (oscillator) and the sleep homeostat (hourglass
timer) (Guo et al., 2018), sleep-wake cycles (e.g., fragmented
sleep and sleep deprivation) will probably have to be consid-
ered when designing chronotherapeutic regimens. Addition-
ally, a novel approach would be to develop and exploit drugs
that target the clock system. For such knowledge to emerge,
there is a need for greater incentives by funding agencies for
the inclusion of circadian aspects in grant calls. For instance,
circadian-omics may help in creating a phase translation map
that would reveal potential translational hurdles and beneﬁts.
In parallel, pharmaceutical and biotechnology companies
should apply existing circadian knowledge to their drug devel-
opment pipeline. Finally, circadian biology is often not incor-
porated in the curriculum of medical schools, and hence,
circadian education and dissemination among medical practi-
tioners will be important for bridging the gap. It is time to take
time seriously.
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